Moderna Resolves the Multibillion-Dollar Litigation Over the Spikevax Vaccine Patent

Moderna has agreed to a massive financial pact, capping its potential legal exposure at $2.25 billion to resolve a high-stakes lawsuit over the technology used in its wildly successful Spikevax COVID-19 vaccine. The agreement, struck just days before a jury trial was scheduled to begin in Delaware, brings an end to a prolonged legal battle with Arbutus Biopharma and Roivant subsidiary Genevant Sciences.

At the heart of the conflict are lipid nanoparticles (LNPs)—tiny fat globules pioneered by Arbutus that are critical for safely delivering mRNA genetic instructions into human cells. Under the newly minted terms, Moderna will pay an upfront lump sum of $950 million in the third quarter of this year. Crucially for Moderna's future margins, the deal absolves the company of any future royalty obligations on its mRNA vaccine sales.

However, the settlement relies on a highly unusual legal mechanism. Moderna will preserve its right to appeal a previous court ruling concerning a World War I-era law known as Section 1498, which centers on a government-contractor defense. If the US Court of Appeals for the Federal Circuit affirms the previous ruling against Moderna, the drugmaker will be forced to pay an additional sum of up to $1.3 billion. Legal experts emphasize that this preserved appeal could establish a massive precedent, ultimately deciding whether companies involved in pandemic-era government programs and emergency contracts are shielded from patent infringement liabilities.

Despite the hefty price tag, the market reacted positively, sending Moderna shares up by 9% in early trading. Arbutus and Genevant had originally been seeking roughly $5 billion, a figure that analysts warned could have pushed Moderna’s balance sheet into acute distress. By avoiding a worst-case scenario, the pharmaceutical giant remains well-funded to advance its crucial late-stage oncology trials and future mRNA treatments.

---

🔖 Sources

Moderna to pay up to $2.25B to end mRNA vaccine patent fight

Moderna Vaccine Patent Deal Sets Up High-Stakes Immunity Appeal

---

Keywords: Spikevax Vaccine Patent

Spikevax Vaccine Patent

---